Selling Medical Devices in the UK and Europe: What Manufacturers need to know in 2026

    Created at: 30 November 2020 - Last updated: 27 August 2026

    Selling Medical Devices in the UK and Europe: What Manufacturers need to know in 2026
    The European and UK medical device markets offer significant opportunities for manufacturers, but successful expansion requires more than obtaining regulatory approval. Companies must understand how evolving regulatory frameworks affect everything from product certification and labelling to distribution models, importer responsibilities and long-term market access.

    Since the introduction of the Medical Device Regulation (MDR) in the European Union and the UK's post-Brexit regulatory framework, medical device manufacturers have faced a more complex compliance environment. At the same time, these changes have increased transparency, traceability and patient safety throughout the healthcare ecosystem.

    For manufacturers planning to enter or expand within Europe and the UK, understanding both regulatory and commercial considerations is essential for sustainable growth.

     

    Understanding the European Regulatory Landscape

    Medical devices placed on the European market are governed primarily by the Medical Device Regulation (MDR) (EU 2017/745).

    The regulation significantly expanded requirements around:

    • Clinical evidence
    • Device traceability
    • Post-market surveillance
    • Economic operator responsibilities
    • Technical documentation
    • Quality management systems

    Unlike the previous Medical Device Directive (MDD), MDR places greater accountability on all parties involved in bringing a product to market.

    These requirements continue to influence how manufacturers structure their European operations and commercial partnerships.


    Selling Medical Devices in the UK

    Since Brexit, the United Kingdom has established its own medical device regulatory framework overseen by the Medicines and Healthcare products Regulatory Agency (MHRA).

    While many regulatory principles remain similar to the EU approach, manufacturers must evaluate additional UK-specific requirements, including:

    • Device registration requirements
    • UK Responsible Person obligations
    • Labelling requirements
    • Market surveillance expectations

    Manufacturers pursuing both UK and EU market access should treat each regulatory pathway separately and incorporate those requirements into their commercial planning from the outset.

     

    Why Compliance Impacts Sales

    Regulatory compliance is often viewed as a technical or quality assurance function. In practice, it has a direct impact on commercial performance.

    Incomplete compliance can affect:

    • Distributor onboarding
    • Product launches
    • Tender participation
    • Customer confidence
    • Supply chain operations
    • Market access timelines

    Companies that integrate regulatory planning with market-entry activities are often able to accelerate commercial growth while reducing operational risks.

    EuroDev Insight

    Many North American manufacturers focus heavily on certification and underestimate the commercial implications of MDR. In our experience, defining the right distribution structure, importer strategy and market-entry plan early often contributes just as much to successful expansion as regulatory readiness.

     

    Understanding Economic Operators

    One of the most significant regulatory developments has been the expanded role of Economic Operators (EOs).

    Under MDR, responsibilities are clearly assigned across the supply chain.

    Manufacturer

    Manufacturers remain ultimately responsible for ensuring that devices comply with applicable regulations.

    Responsibilities include:

    • Maintaining technical documentation
    • Demonstrating conformity
    • Implementing post-market surveillance
    • Handling vigilance reporting
    • Ensuring product traceability

    Authorised Representative

    Manufacturers based outside the European Union must appoint an EU Authorised Representative.

    The Authorised Representative acts as an important regulatory contact point and supports communication with European authorities where required.

    Importer

    Under MDR, importers play a much more active role than under previous regulations.

    Importers are expected to verify that:

    • Required conformity assessments have been completed
    • Appropriate documentation exists
    • Labels comply with requirements
    • UDI obligations are met
    • Products are suitable for placement on the market

    Distributor

    Distributors must also perform compliance verification activities and maintain processes for complaints, recalls and other post-market obligations.

    This differs significantly from the more passive role distributors often held under the previous regulatory framework.

     

    The Importance of UDI and Traceability

    The introduction of the Unique Device Identification (UDI) system represents one of the most important changes under MDR.

    UDI improves traceability throughout the device lifecycle and supports:

    • Product identification
    • Recall management
    • Post-market surveillance
    • Regulatory oversight
    • Patient safety

    UDI requirements must be reflected across:

    • Product labels
    • Packaging
    • Technical documentation
    • Internal systems

    Manufacturers that fail to adequately plan for UDI implementation often face additional compliance and operational challenges.

    The UDI framework also supports the wider objectives of EUDAMED, the European Database on Medical Devices, which aims to increase transparency across the European healthcare sector.


    Choosing the Right Distribution Strategy

    Selecting the right route to market is one of the most important decisions when entering Europe.

    Common approaches include:

    Exclusive Distributor Model

    Suitable for manufacturers focused on one or two target markets.

    Multi-Country Distribution Network

    Allows broader European coverage through multiple specialised partners.

    Direct Sales Organisation

    Offers greater control but requires larger investments in infrastructure and personnel.

    Hybrid Approach

    Combines direct commercial activities with strategic distributors.

    Each model creates different commercial and regulatory considerations that should be assessed before launch.

    EuroDev Insight

    Many manufacturers initially choose distributors based solely on sales coverage. However, a distributor's understanding of MDR obligations, regulatory communication and complaint handling procedures can be equally important when building a sustainable European presence.


    Common Challenges Medical Device Manufacturers Face

    Although every company is different, several recurring issues continue to emerge during European expansion projects.

    Viewing Compliance as a One-Time Activity

    Regulatory compliance is an ongoing process that extends throughout the device lifecycle.

    Defining Economic Operator Roles Too Late

    Manufacturer, importer and distributor responsibilities should be clearly established before commercial launch.

    Underestimating Documentation Requirements

    Post-market surveillance, technical documentation updates and vigilance activities require long-term resources.

    Separating Commercial and Regulatory Planning

    Sales, regulatory and operational teams should work together throughout the market-entry process.

    Overlooking Country-Specific Requirements

    Europe consists of many individual markets, each with its own purchasing behaviours, healthcare systems and language requirements.


    Key Considerations Before Expanding into Europe and the UK

    Before launching a product, manufacturers should evaluate:

    •  MDR Readiness
    •  UK regulatory requirement
    •  UDI implementation  
    •  Economic operator structure
    •  Distribution strategy
    •  Labelling compliance
    •  Post-market surveillance processes   
    •  Market prioritisation
    •  Commercial launch planning  

     

    Addressing these factors early helps reduce delays and improve long-term success.

    Key Takeaways

    • MDR continues to influence how medical devices are commercialised throughout Europe.
    • UK market access requires separate regulatory consideration following Brexit.
    • Manufacturers, importers, distributors and authorised representatives all have clearly defined responsibilities.
    • UDI and traceability remain central requirements for compliance.
    • Regulatory planning and commercial strategy should be aligned from the beginning.
    • Successful expansion depends on both compliance and execution.

     

    Written by EuroDev Med Tech & Life Sciences team.

    Sources

    1. European Parliament and Council. Regulation (EU) 2017/745 on Medical Devices (MDR).
    [eur-lex.europa.eu]

    2.European Commission. Medical Devices Sector.
    [health.ec.europa.eu]

    3.European Commission. EUDAMED.
    [health.ec.europa.eu]

    4.European Commission. MDCG Guidance Documents.
    [health.ec.europa.eu]

    5.MHRA. Regulating Medical Devices in the UK.
    [gov.uk]

    6.MHRA. UK Responsible Person Guidance.
    [gov.uk]

    7.MedTech Europe.
    [medtecheurope.org]

    8.European Commission. MDR Factsheet for Economic Operators. [health.ec.europa.eu]

    Spread the value

    Category